Targeted Oncology9h
The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS G12C-NSCLC, Adding Nivolumab to Tivozanib Yields No benefit in RCC, and More
NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.
Targeted Oncology3d
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2-Overexpressing Cancers
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
Nasdaq14d
Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial
According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...
Business Wire15d
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...
Nature20d
Billion-dollar deals bolster oncology research
Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...